Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival by Lokhorst, H.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/152656
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
Growth differentiation factor 15 (GDF15) promotes
osteoclast differentiation and inhibits osteoblast dif-
ferentiation and high serum GDF15 levels are associ-
ated with multiple myeloma bone disease
Multiple myeloma (MM) is a hematologic cancer
caused by malignant plasma cells in the bone marrow. A
characteristic feature of this cancer is the destruction of
bone, which affects nearly all myeloma patients. The
osteolytic bone disease is caused by an increased number
and activity of osteoclasts, combined with a reduced
number and dysfunction of osteoblasts.1
Growth differentiation factor 15 (GDF15) is a member
of the transforming growth factor-beta family that has
been shown to play a role in several types of cancer,
inflammation, cardiovascular disease and many other
pathologies.2 Stromal cells in the bone marrow of MM
patients overexpress GDF15,3,4 and high levels of GDF15
in the circulation of myeloma patients are associated
with a poor prognosis.4,5 Moreover, GDF15 was recently
shown to enhance the tumor-initiating and self-renewal
potential of malignant plasma cells, as well as conferring
drug resistance.4,5
The effects of GDF15 on bone cells are unclear. One
study demonstrated an important role for GDF15 in bone
remodeling during hypoxia.6 In particular, GDF15 pro-
duced by osteocytes promoted osteoclast differentiation
both in vitro and in vivo.6 Moreover, GDF15 was shown to
promote osteoclast formation in prostate cancer metasta-
sizing to bone.7 In contrast, another study showed that
GDF15 inhibited osteoclast formation in vitro.8 These
studies were, however, performed on mouse bone mar-
row mononuclear cells or murine macrophage-like cell
lines, and how GDF15 affects human osteoclast differen-
tiation is not reported. Moreover, little is known on how
GDF15 affects osteoblast differentiation. Hence, we
wanted to characterize the effect of GDF15 on the differ-
entiation of human osteoclasts and osteoblasts and to
measure GDF15 in serum from a well-characterized
cohort of myeloma patients to see whether high GDF15
levels are associated with osteolytic bone disease. 
GDF15 was measured by a multiplex assay (The MIL-
LIPLEX MAP Human Cancer/Metastasis Biomarker Panel
1, Millipore Corporation, Billerica, MA, USA) in serum
samples obtained at diagnosis from 138 myeloma
patients and 58 age- and sex-matched healthy controls.
Out of 21 tested cytokines, 12 were differently expressed
in patients compared with controls (for the full list and
details on multiple testing correction, see Online
Supplementary Data).9 The patients’ samples were collect-
ed for the Nordic Myeloma Study Group during a ran-
domized, phase 3 clinical trial which compared the effect
of two different doses of pamidronate on bone. The bone
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Figure 1. GDF15 serum
levels in myeloma
patients at the time of
diagnosis are higher in
patients with osteolytic
lesions. (A) GDF15 was
measured in serum sam-
ples from MM patients
(n=138) and healthy con-
trols (n=58). Differences
between groups were
analyzed by the Kruskal-
Wallis test and bars indi-
cate median values. (B)
Bone disease status at
inclusion was available
for 132 of the myeloma
patients, and the patients
were divided into groups
based on degree of bone
destruction: limited, ≤3
osteolytic lesions (n=51),
advanced, >3 osteolytic
lesions (n=51) and dif-
fuse osteoporosis, with-
out lesions (n=14).
Serum GDF15 levels in
these groups were com-
pared with serum GDF15
levels in patients without
bone disease (n=16)
using the Dunn multiple
comparison test. Bars
indicate median values.
(C) Kaplan-Meier plot of
the appearance of skele-
tal-related events (SRE) in
myeloma patients with
serum GDF15 ≤1.08
ng/mL or GDF15 >1.08
ng/mL. (D) Kaplan-Meier
plot of survival in myelo-
ma patients with serum
GDF15 ≤1.08 ng/mL or
GDF15 >1.08 ng/mL.
A B
C D
disease was, therefore, particularly well characterized in
this study.10, 11
We found that the concentration of GDF15 was signif-
icantly higher in serum obtained from myeloma patients
(median 1.08 ng/mL; range, 0.17-28.08) than from
healthy controls (median 0.46 ng/mL; range, 0.02-1.68;
independent samples Kruskal-Wallis test P≤0.0001, cor-
rected for multiple comparisons, P≤0.02) (Figure 1A).
Moreover, the level of serum GDF15 was higher in
patients with more advanced osteolytic bone disease (>3
osteolytic lesions, n=51, median 1.44 ng/mL; range, 0.30-
6.78) than in patients without osteolytic lesions (n=16,
median 0.84 ng/mL; range, 0.22-10.84) at inclusion
(P<0.05, Dunn multiple comparison test) (Figure 1B), sup-
porting the concept that GDF15 might play a role in
myeloma bone disease. The difference in serum GDF15
levels between myeloma patients with limited bone dis-
ease (≤3 osteolytic lesions, n=51, median 1.07 ng/mL;
range, 0.17-7.01) and myeloma patients with no bone
disease, and the difference between myeloma patients
with osteoporosis but no lesions (n=14, median 1.01
ng/mL; range, 0.36- 4.26) and myeloma patients with no
bone disease were not statistically significant. Skeletal-
related events (defined as pathological fractures, radio-
therapy or surgery to bone, new vertebral compression,
symptomatic new or progressive osteolytic lesions and
hypercalcemia) were evaluated every third month.10 For
patients with serum GDF15 levels equal to or less than
the median serum GDF15 level (GDF15 ≤1.08 ng/mL,
n=65), the time to skeletal-related events was not
reached, while estimated time from inclusion to skeletal-
related events in the group of patients with serum GDF15
>1.08 ng/mL was 35 months (n= 59). This difference was
not, however, statistically significant (P=0.08 log-rank
test, Figure 1C). The median time from inclusion to skele-
tal-related events for the whole group of patients with
recorded skeletal status was 42 months (n=124). In line
with what has been reported previously5 we found that
low serum GDF15 concentration was associated with
better overall survival: the median survival of patients
who had a serum GDF15 ≤1.08 ng/mL  (n=69) was esti-
mated to be 82 months, while the median survival for
patients with GDF15 levels above 1.08 ng/mL was esti-
mated to be 35 months  (P=0.002, log-rank test) (Figure
1D). The overall median survival for the 138 myeloma
patients was estimated to be 59 months. An increase in
serum GDF15 levels of 1 ng/mL led to an increased risk
of death of 1.187 (univariate Cox regression, P<0.001).  
Importantly, levels of serum GDF15 correlated with
levels of markers for osteoclast activity, carboxy-terminal
crosslinked telopeptide of type I collagen (CTX1)
(Spearman rho 0.40, P≤0.001) and carboxy-terminal
haematologica 2015; 100:e512
LETTERS TO THE EDITOR
Figure 2. GDF15 promotes osteoclastogenesis and inhibits osteoblastogenesis in vitro. (A) Peripheral blood monocytes were treated with
macrophage colony-stimulating factor (M-CSF) (30 ng/mL) and left to differentiate in the presence of RANKL (50 ng/mL) with or without
osteoprotegerin (OPG 200 ng/mL) and various concentrations of GDF15 as indicated. On day 14 TRAP-positive multinucleated cells were
counted. Error bars = SEM of triplicate wells. The figure shows one representative experiment out of three. (B) Representative images of
TRAP-stained osteoclasts. (C) Alkaline phosphatase (ALP) activity/mg DNA was determined in human bone marrow-derived mesenchymal
stem cells (hMSC) differentiated in osteogenic medium containing L-ascorbic acid (50 mM), dexamethasone (10-8 M) and β-glycerophos-
phate (10 mM) for 7 days. Error bars = SEM of triplicate wells. (D) hMSC were differentiatied for 17 days in osteogenic media and stained
with alizarin red-S (ARS) to quantify degree of mineralization. Error bars = SEM of duplicate experiments. (E) mRNA expression of RUNX2,
(F) COL1A1 and  (G) BGLAP in hMSC at day 7 after differentiation. Bars represent mean of triplicate experiments, error bars represent
maximal relative quantity. The figure shows one representative experiment of three.
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crosslinked telopeptide of type I collagen generated by
matrix metalloproteinases (ICTP) (Spearman rho 0.63,
P≤0.001), supporting an association between high GDF15
levels and increased osteoclast activation. In contrast,
serum GDF15 concentration did not correlate with mark-
ers of osteoblast activity, bone-specific alkaline phos-
phatase (rho -0.06, P=0.52) or amino-terminal propeptide
of procollagen (PINP) (rho 0.15, P=0.07). 
To evaluate the effect of GDF15 on osteoclast differen-
tiation in vitro we differentiated osteoclasts from periph-
eral blood mononuclear cells (n=3) or from purchased
pre-osteoclasts (Lonza Inc., Allendale, NJ, USA; n=2).
The cells were cultured in osteoclast medium [a-MEM
with human serum (20%), macrophage colony-stimulat-
ing factor (M-CSF; 30 ng/mL) and receptor activator of
NF-κB ligand (RANKL; 50 ng/mL)] for up to 14 days with
or without GDF15 and thereafter stained for tartrate
resistant acid phosphatase (TRAP). We found that GDF15
dose-dependently increased the number of multi-nucleat-
ed TRAP-positive cells differentiated from peripheral
blood mononuclear cells (Figure 2A,B). When we used
pre-osteoclasts as precursor cells, however, the optimal
concentration was in the lower range (2-20 ng/mL) while
higher concentrations had no effect (Online Supplementary
Figure S1). GDF15 could not promote osteoclast differen-
tiation in the absence of RANKL (data not shown), and the
effect of GDF15 was inhibited by osteoprotegerin, sug-
gesting that GDF15 acts cooperatively with RANKL.
Hence, our results support previous studies showing an
osteoclast-promoting effect of GDF15.6,7
To investigate whether GDF15 influences osteoblast
differentiation in vitro we cultured human bone marrow-
derived mesenchymal stem cells (Lonza Inc., Allendale,
NJ, USA) (n=3) in osteogenic medium containing L-ascor-
bic acid (50 mM), dexamethasone (10-8M) and β-glyc-
erophosphate (10 mM) in the presence or absence of
GDF15 for up to 17 days. Alkaline phosphatase activity is
considered an early marker of osteoblast differentiation,
and was quantified after 7 days as described previously.12
In all donors, GDF15 dose-dependently inhibited alkaline
phosphatase-activity (Figure 2C). Moreover, late differen-
tiation, as evaluated by the cells’ ability to mineralize
matrix, was reduced in the presence of GDF15 (Figure
2D,E). Supporting reduced differentiation in the presence
of GDF15, mRNA levels of osteoblast markers RUNX2,
type I collagen (COL1A1) and osteocalcin (bone gamma-
carboxyglutamic acid-containing protein, BGLAP) were
decreased upon GDF15 treatment (Figure 2F-H). 
GDF15 influenced in vitro differentiation of osteoclasts
and osteoblasts at concentrations ranging from 5-100
ng/mL, while the median concentration of GDF15 in
serum obtained from myeloma patients was 1.08 ng/mL
(Figure 1A). To compare levels of GDF15 in bone marrow
plasma with levels in blood serum we measured GDF15
by the multiplex assay (Millipore) in a set of paired bone-
marrow plasma and serum samples obtained from
myeloma patients (n=16) (Online Supplementary Figure
S2). In accordance with previously published data,5 there
was a strong correlation between bone marrow plasma
levels and serum levels (Spearman rho = 0.97, P<0.0001),
which implies that levels of GDF15 in serum reflect levels
of GDF15 in bone marrow. In our set of samples levels in
bone marrow plasma appeared approximately 25%
lower than levels in serum (Online Supplementary Figure
S2). However, this was not observed in a previous study.5
Unprocessed GDF15 is stored in extracellular matrix,13
and might be activated/released locally. Hence, future
studies should address the relationship between circulat-
ing levels of GDF15 and levels locally in the bone mar-
row, and whether GDF15 in concentrations found locally
in myeloma bone marrow influence bone homeostasis in
vivo. Importantly, levels of GDF15 in bone marrow plas-
ma from myeloma patients were elevated compared with
levels in bone marrow plasma from healthy persons,5
suggesting that cells in myeloma bone marrow are
exposed to higher concentrations of GDF15 than cells in
a healthy bone marrow.
In conclusion, serum GDF15 levels are elevated in
myeloma patients with advanced osteolytic bone disease
compared to the levels in patients with no lesions, and
correlate with serum markers for osteoclast activity. We
found that GDF15 increases osteoclast differentiation
and at the same time inhibits osteoblast differentiation in
vitro. Hence, GDF15 might play a role in uncoupling bone
formation and resorption in multiple myeloma. Our
results presented here and recent reports by others4,5 sug-
gest that GDF15 may be of interest as a target for treat-
ment of multiple myeloma.   
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